IQVIA Holdings, Inc. · NYSE:IQV
IQVIA — Quintiles — 2014 Wells Fargo Healthcare Conference
19 slides from IQVIA's conference presentation, Jun 17, 2014
Slide 1: 2014 Wells Fargo Healthcare Conference
2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright © 2013 Quintiles
Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures
Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements refl
Slide 3: Enterprise Vision and Strategy
Enterprise Vision and Strategy Quintiles We bring people and Vision knowledge together for a healthier world Our Strategic Agenda Profitable growth at above market rates Lead with investments Biopharma Product Integrated that leverage our scale Healthcare Services Development Our Customer Promise an
Slide 4: Stability and Long-term Momentum
Stability and Long-term Momentum Consistent Gains Underpinned with a Low Customer Concentration Adjusted Service Revenues(1) Adjusted EBITDA(2) ’10 – ’13 CAGR = 8.3% ’10 – ’13 CAGR = 9.7% 4,000 $3,808 700 $3,692 $3,295 $612 600 $544 $2,997 3,000 $490 500 $463 $ Millions $ Millions 400 2,000 300 1,00
Slide 5: Continued Momentum in 2014
Continued Momentum in 2014 Financial Results - Three Months Ended March 31, 2014 FINANCIAL HIGHLIGHTS OTHER HIGHLIGHTS 8.4% Constant Currency Revenue(1) 1.27x Book-to-bill ratio - 8.6% in Product Development - 1.30x in Product Development -7.9% in Integrated Healthcare Services - 1.15x in Integrated
Slide 6: Attractive and Growing Market
Attractive and Growing Market ~$200bn addressable market with growth of 5% - 8% per year from 2013 - 2016 Product Development Approval Phase Commercial Healthcare Phase I Phase II Phase III IV Delivery Product Development Services Integrated Healthcare Services (“IHS”) (93% of Operating Profit) (3)
Slide 7: Evolving Biopharma Landscape
Evolving Biopharma Landscape Growth, inefficiency and complexity play to Quintiles’ strength The median number of procedures per trial increased by 57% between 2003 and 20111 Increasing Trial Complexity R&D spending grew Over 3,000 ongoing clinical trials involve a biomarker or Personalized R&D ~1.5
Slide 8: Deep Customer Relationships
Deep Customer Relationships Largest Backlog in Industry Providing Consistency, Sustainability and Diversification Worked with all top 20 biopharma companies in each of last 11 years All of our top 25 key customers worked with both Quintiles segments: PD and IHS $100mm+ service revenues from at least
Slide 9: The Leader in BioPharma Services
The Leader in BioPharma Services Why We Win = Enhanced Value for Customers • Clearly differentiated service offerings Leader of innovative models > Improving probability of success > Depth and breadth of service offerings > Provided services to develop or commercialize enabled the win of 2 sole prov
Slide 10: Product Development
Product Development Accelerating pipelines using science, technology and global delivery Ph - I Ph - II Ph - III Ph-IIIB & IV Product Development Services • Core Segment representing 77% of Consolidated Deep Science, Therapeutic, & Service Revenues and 93% of Segment Income from Operations(1) Regula
Slide 11: Integrated Healthcare Services
Integrated Healthcare Services Improving the probability of commercial success Phase II & III Commercial Healthcare Delivery Integrated Healthcare Services Offerings Integrated Healthcare Services Commercial Services: • Contract Sales • IHS Segment represents 23% of Consolidated • Market Entry / Mar
Slide 12: Encore
Encore Real World Evidence Provides Improved Outcomes Transaction • Announced May 12, 2014 • Capability enhancing transaction Rationale • Enhances provider relationships and access to population health market • Adds EMR and meaningful use capabilities • Natural supplement to Real World Late Phase bu
Slide 13: An Attractive Investment
Quintiles An Attractive Investment Strong free cash flow Best in industry operating margins with a consistent focus on process and productivity leverage Deep and diverse customer relationships with no customer contributing 10% or more of revenues Long-term consistent financial performance First move
Slide 14: Appendix
Appendix 14
Slide 15: Adjusted Service Revenues Reconciliation
Adjusted Service Revenues Reconciliation Adjusted Service Revenues Reconciliation Year Ended December 31 (In Thousands) 2013 2012 2011 2010 Non-GAAP Adjusted Service Revenues: GAAP Service Revenues as Reported $3,808,340 $3,692,298 $3,294,966 $3,060,950 Deconsolidation of PharmaBio -– – – (64,198) A
Slide 16: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Adjusted EBITDA Reconciliation Year Ended December 31 (In Thousands) 2013 2012 2011 2010 Non-GAAP Adjusted EBITDA: GAAP Net Income as Reported $226,027 $176,631 $240,327 $165,255 Interest Expense, Net 119,571 131,304 105,126 137,631 Income Tax Expense 95,965 93,364 15,
Slide 17: Adjusted Net Income Reconciliation
Adjusted Net Income Reconciliation Adjusted Net Income Reconciliation Year Ended December 31 (In Thousands) 2013 2012 2011 2010 Non-GAAP Adjusted Net Income: GAAP Net Income as Reported $226,027 $176,631 $240,327 $165,255 Net (Income) Loss Attributable to Noncontrolling Interests 564 915 1,445 (4,65
Slide 18: GAAP – Non-GAAP Reconciliation
Income Statement GAAP – Non-GAAP Reconciliation 2014 2013 Selling, Income Net Income Selling, Income Net Income Three Months Ended March 31 General and from Attributable General and from Attributable (millions of dollars) Administrative Operations to Quintiles Administrative Operations to Quintiles
Slide 19: Constant Currency Reconciliation Service Revenues and Income from Operations
Constant Currency Reconciliation Service Revenues and Income from Operations (millions of dollars) Three Months Ended March 31 Year on Year Growth Exchange Exchange Consolidated Actual Impact Constant Actual Impact Constant Service Revenues $ 1,005.3 $ (0.5) $ 1,005.8 8.4% 0.0% 8.4% Income from Oper